Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia
Stefanie Gierer1, Heike Hofmann-Winkler1, Waleed H. Albuali, Stephanie Bertram, Abdullah M. Al-Rubaish, Abdullah A. Yousef, Awatif N. Al-Nafaie, Amein K. Al-Ali, Obeid E. Obeid, Khaled R. Alkharsah, and Stefan Pöhlmann1
Author affiliations: German Primate Center, Göttingen, Germany (S. Gierer, H. Hofmann-Winkler, S. Bertram, S. Pöhlmann); University of Dammam, Dammam, Saudi Arabia (W.H. Albuali, A.M. Al-Rubaish, A.A. Yousef, A.N. Al-Nafaie, A.K. Al-Ali, O.E. Obeid, K.R. Alkharsah).
Figure 2. . Analysis of serum samples with known neutralizing activity. Neutralization of transduction driven by the Middle East respiratory syndrome coronavirus spike protein (MERS-S) (A), G protein of vesicular stomatitis virus (B), and S protein of human coronavirus NL63 (NL63-S) (C) were determined as described for Figure 1, except that serum with known reactivity to MERS-S and NL63-S and serum from 2 patients at King Fahd Hospital of the University in Alkhobar, Saudi Arabia, that neutralized NL63-S–mediated transduction (Figure 1, panel A) were analyzed. Transduction of target cells in the absence of serum was set at 100%.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.